Here's the hot stuff from Pfizer
$PFE (+0,23%) (NYSE: PFE) Q2 2026 Earnings Release, delivered fresh on August 4, 2026, before the U.S. markets opened:
🚀 Top-line performance & non-COVID segment drive growth
Pfizer beat Wall Street’s revenue expectations in the second quarter of 2026 thanks to strong demand for newly launched drugs and acquisitions:
Total revenue: Reached $15.0 billion (operating +1% YoY), significantly exceeding analysts’ estimates of ~$14.45 billion.
Excluding COVID products (Comirnaty & Paxlovid): Operating revenue grew by +5% YoY.
Newly launched & acquired products: Grew on an operating basis by +18% YoY .
🔮 Profitability, Special Charges & Efficiency Initiative
Pfizer clearly beat expectations on adjusted earnings, while one-time items weighed on GAAP earnings:
Adjusted Diluted EPS: Reached $0.77 (compared to $0.78 in the same quarter last year) and significantly beat the consensus estimate of $0.68!
GAAP earnings: Reports a net loss of -0.04 USD per share , primarily due to $4.3 billion in non-cash impairments (non-cash intangible asset impairments).
New Cost-Cutting Program: Pfizer announces an expansion of its cost optimization program and aims for an additional $2.5 billion in net savings by 2029.
🤖 Revenue Forecast Upgrade
Thanks to strong momentum in its operating business, CEO Albert Bourla is raising the revenue target for the full year 2026:
FY 2026 revenue forecast raised: Raised by $500 million at the midpoint to $60.5 to $62.5 billion (previously $59.5–$62.5 billion).
FY 2026 Adjusted Diluted EPS reaffirmed: Remains in the range of $2.80 to $3.00 (which absorbs, among other things, charges related to Innovent Biologicstransaction).
⚡ 💡 Jack’s take
Pfizer is proving that the transition away from purely COVID-driven one-time gains is succeeding! Revenue of $15.0 billion, an 18% increase in operating profit from core growth drivers, and a significant EPS beat ($0.77 vs. $0.68 consensus) underscore the operational turnaround. With its raised revenue guidance and a refined cost-cutting program, Pfizer is strengthening the foundation for sustainable growth and securing its generous dividend!
